A Study of Continuous Subcutaneous Insulin Infusion (CSII) Pump Function in Subjects With Type 1 Diabetes With Recombinant Human Hyaluronidase (rHuPH20)

NCT ID: NCT03662334

Last Updated: 2019-02-01

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE4
• Total Enrollment: 14 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2013-10-03
• Study Completion Date: 2014-02-27

Brief Summary

The goal of this study is to determine if Hylenex recombinant leads to changes in the insulin time-action profiles and glucose responses when preadministered in the setting of continuous subcutaneous insulin infusion (CSII) compared to CSII without Hylenex recombinant (sham injection).

Detailed Description

There is a recognized need for more rapid insulin action than is available from current rapid-acting analog products. In addition, current products have inconstant absorption and action profiles over the course of infusion set life. Previous human studies of prandial insulin preparations have used co-mixtures of rHuPH20 (study drug) with insulin delivered to study participants by subcutaneous injection and have demonstrated acceleration of insulin absorption and action. CSII has been used clinically for the treatment of diabetes over the last three decades, and a previous study using a co-mixture of rHuPH20 during CSII showed that the combination resulted in a more consistent and ultrafast profile of insulin absorption and action across infusion set use as compared to rapid analog insulin alone.

Conditions

Type 1 Diabetes Mellitus

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

Hylenex recombinant

Comparing the preadministration of Hylenex recombinant in the setting of continuous subcutaneous insulin infusion (CSII).

Group Type: EXPERIMENTAL

Rapid Acting insulin with pre-treatment of rHuPH20

Intervention Type: DRUG

Hylenex recombinant will be administered via infusion sets and insulin pumps. These will be compatible with component tubing system attached to the insulin infusion site and will be placed in the lower abdominal area.

Sham Injection

Comparing the preadministration of a sham injection in the setting of CSII.

Group Type: SHAM_COMPARATOR

Sham injection

Intervention Type: DEVICE

A sham injection will be administered via infusion sets and insulin pumps. These will be compatible with component tubing system attached to the insulin infusion site and will be placed in the lower abdominal area.

Interventions

Rapid Acting insulin with pre-treatment of rHuPH20

Hylenex recombinant will be administered via infusion sets and insulin pumps. These will be compatible with component tubing system attached to the insulin infusion site and will be placed in the lower abdominal area.

Intervention Type: DRUG

Sham injection

A sham injection will be administered via infusion sets and insulin pumps. These will be compatible with component tubing system attached to the insulin infusion site and will be placed in the lower abdominal area.

Intervention Type: DEVICE

Other Intervention Names

Humalog; Hylenex; placebo

Eligibility Criteria

Inclusion Criteria

1. Male or female participants between the ages 18 and 65 years, inclusive.

2. Females of child-bearing potential must agree to use a standard and effective means of birth control for the duration of the study. Adequate contraceptive measures include oral or injectable contraceptives, sterilization, intra-uterine device (IUD), barrier methods, or abstinence.

3. Participants with type 1 diabetes mellitus treated with insulin (multiple daily injections or continuous subcutaneous insulin infusion [CSII]) diagnosed ≥ 12 months prior to enrollment

4. Body mass index (BMI) 18.0 to 32.0 kilograms per meters squared (kg/m^2)

5. HbA1c (glycated hemoglobin A1c) ≤ 10% based on local laboratory results

6. Fasting C-peptide < 0.6 nanograms per milliliter (ng/mL)

7. Current treatment with insulin <1.2 Units per kg per day (U/kg/day)

8. Participant should be in good general health based on medical history and physical examination, without medical conditions that might prevent the completion of study drug injections and assessments required in this protocol

Exclusion Criteria

1. Inability to comply with study requirements as judged by the Investigator

2. Known or suspected allergy to any component of any of the study drugs in this trial

3. A participant who has proliferative retinopathy or maculopathy, severe gastroparesis, and/or severe neuropathy, in particular autonomic neuropathy, as judged by the Investigator

4. As judged by the Investigator, clinically significant active disease of the gastrointestinal, cardiovascular (including a history of arrhythmia or conduction delays on electrocardiogram), hepatic, neurological, renal, genitourinary, or hematological systems

5. As judged by the Investigator, uncontrolled hypertension (diastolic blood pressure ≥ 100 millimeters of mercury [mmHg] and/or systolic blood pressure ≥ 160 mmHg after 5 minutes in the supine position)

6. History of any illness or disease that in the opinion of the Investigator might confound the results of the trial or pose additional risk in administering the study drugs to the participant

7. As judged by the Investigator, clinically significant findings in routine laboratory data. Anemia with hemoglobin less than lower limits of normal at screening is specifically exclusionary

8. Use of drugs that may interfere with the interpretation of trial results or are known to cause clinically relevant interference with insulin action, glucose utilization, or recovery from hypoglycemia, or drugs not permitted according to Hylenex recombinant package insert

9. Recurrent major hypoglycemia or hypoglycemic unawareness, as judged by the Investigator

10. Current addiction to alcohol or substances of abuse as determined by the Investigator

11. Blood donation (> 500 mL) within the previous 8 weeks (56 days) prior to Day -1 of Treatment Period 1

12. Pregnancy, breast-feeding, the intention of becoming pregnant, or not using adequate contraceptive measures (adequate contraceptive measures consist of sterilization, IUD, oral or injectable contraceptives, or barrier methods)

13. Mental incapacity, unwillingness, or language barriers precluding adequate understanding or cooperation in this study

14. Participation in any other clinical trial and receipt of any investigational drug within 4 weeks of Day -1 of Treatment Period 1

15. Any condition (intrinsic or extrinsic) that in the judgment of the Investigator will interfere with trial participation or evaluation of data

16. Positive for human immunodeficiency virus (HIV), Hepatitis C or Hepatitis B

17. Tobacco and nicotine use within 3 months prior to Day 1 of Treatment Period 1 or use during the study

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Halozyme Therapeutics

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Profil Institute for Clinical Research

Chula Vista, California, United States

Countries

United States

Related Links

http://www.halozyme.com

Halozyme Therapeutics

Other Identifiers

HALO-117-406

Identifier Type: -

Identifier Source: org_study_id